2. Aletaha D., Neogi T., Silman A.J. et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569–81. https://doi.org/10.1002/art.27584. PMID: 20872595.

3. Fransen J., van Riel P.L. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009; 35(4): 745–57, vii–viii. https://doi.org/10.1016/j.rdc.2009.10.001. PMID: 19962619.

4. Государственный реестр лекарственных средств Минздрава России. Инструкции по медицинскому применению лекарственных препаратов с МНН метотрексат. Доступ: https:// grls.rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=метотрексат&lf=&TradeNmR=&O wnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&regtype=1%2c6&pageSize=10&order= Registered&orderType=desc&pageNum=1 (дата обращения – 01.03.2024).

5. Donahue K.E., Schulman E.R., Gartlehner G. et al. Comparative effectiveness of combining MTX with biologic drug therapy versus either MTX or biologics alone for early rheumatoid arthritis in adults: A systematic review and network meta-analysis. J Gen Intern Med. 2019; 34(10): 2232–45. https://doi.org/10.1007/s11606-019-05230-0. PMID: 31388915.

6. Verschueren P., De Cock D., Corluy L. et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015; 74(1): 27–34. https://doi.org/10.1136/annrheumdis-2014-205489. PMID: 25359382.

7. De Jong P.H., Hazes J.M., Han H.K. et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014; 73(7): 1331–39. https://doi.org/10.1136/annrheumdis-2013-204788. PMID: 24788619. PMCID: PMC4078755.

8. Tornero Molina J., Calvo Alen J., Ballina J. et al. Recommendations for the use of parenteral methotrexate in rheumatic diseases. Reumatol Clin (Engl Ed). 2018; 14(3):142–49. https://doi.org/10.1016/j.reuma.2016.12.001. PMID: 28082032.

9. Schiff M.H., Sadowski P. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis. Rheumatol Int. 2017; 37(2): 213–18. https://doi.org/10.1007/s00296-016-3621-1. PMID: 28012023.

10. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е. с соавт. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016; 3: 247–265.

11. Simon L.S. Non-steroidal anti-inflammatory drugs and their benefits and harms: the challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported. Arthritis Res Ther. 2015; 17(1): 130. https://doi.org/10.1186/s13075-015-0650-1. PMID: 25994069. PMCID: PMC4440245.

12. Palmowski Y., Buttgereit T., Dejaco C. et al. «Official view» on glucocorticoids in rheumatoid arthritis. A systematic review of international guidelines and consensus statements. Arthritis Care Res (Hoboken). 2017; 69(8): 1134–41. https://doi.org/10.1002/acr.23185. PMID: 28029750.

13. Hazlewood G.S., Barnabe C., Tomilison G. et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: Abridged Cochrane systemic review and network meta-analysis. BMJ. 2016: 353: i1777. https://doi.org/10.1136/bmj.i1777. PMID: 27102806. PMCID: PMC4849170.

14. Visser K, Katchamart W, Loza E. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009; 68(7): 1086–93. https://doi.org/10.1136/ard.2008.094474. PMID: 19033291. PMCID: PMC2689523.

15. Smolen J.S., Landewe R., Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6): 960–77. https://doi.org/10.1136/annrheumdis-2016-210715. PMID: 28264816.

16. Golicki D., Newada M., Lis J. et al. Leflunomide in monotherapy of rheumatoid arthritis: Meta-analysis of randomized trials. Pol Arch Med Wewn. 2012; 122(1–2): 22–32. https://doi.org/10.20452/pamw.1131. PMID: 22353705.

17. Scire C.A., Lunt M., Marshall T. et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2014; 73(9): 1677–82. https://doi.org/10.1136/annrheumdis-2013-203339. PMID: 23749581. PMCID: PMC4145442.

18. Norvang V., Sexton J., Kristianslund E.K. et al. Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: Data from real-life follow-up in the NOR-DMARD study. RMD Open. 2018; 4(2): e000773. https://doi.org/10.1136/rmdopen-2018-000773. PMID: 30488000. PMCID: PMC6242030.

19. Aletaha D., Alasti F., Smolen J.S. Optimisation of a treat-to-target approach in rheumatoid arthritis: Strategies for the 3-month time point. Ann Rheum Dis. 2016; 75(8): 1479–85. https://doi.org/10.1136/annrheumdis-2015-2083. PMID: 26420577.

20. Pokharel G., Deardon R., Barnabe C. et al. Joint estimation of remission and response for methotrexate-based DMARD options in rheumatoid arthritis: A Bivariate network meta-analysis. ACR Open Rheumatol. 2019; 1(8): 471–79. https://doi.org/10.1002/acr2.11052. PMID: 31777827. PMCID: PMC6858043.

21. Buckley F., Finckh A., Huizinga T.W.J. et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with Inadequate response to conventional DMARDs: A network meta-analysis. J Manag Care Spec Pharm. 2015; 21(5): 409–23. https://doi.org/10.18553/jmcp.2015.21.5.409. PMID: 25943002. PMCID: PMC10397966.

22. Nam J.L., Ramiro S., Gaujoux-Viala C. et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014; 73(3): 516–28. https://doi.org/10.1136/annrheumdis-2013-204577. PMID: 24399231.

23. Насонов Е.Л. Биоаналоги в ревматологии. Научно-практическая ревматология. 2016; 54(6): 628–640.

24. Smolen J.S., Goncalves J., Quinn M. et al. Era of biosimilars in rheumatology: Reshaping the healthcare environment. RMD Open. 2019; 5(1): e000900. https://doi.org/10.1136/rmdopen-2019-000900. PMID: 31245050. PMCID: PMC6560670.

25. Durez P. Switching of biologics in RA patients who do not respond to the first biologic. Joint Bone Spine. 2018; 85(4): 395–97. https://doi.org/10.1016/j.jbspin.2018.02.001. PMID: 29452302.

26. Cavalli G., Favalli E.G. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2019; 15(12): 1313–22. https://doi.org/10.1080/1744666X.2020.1686976. PMID: 31663390.

27. Smolen J.S., Breedveld F.C., Burmester G.R. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75(1): 3–15. https://doi.org/10.1136/annrheumdis-2015-207524. PMID: 25969430. PMCID: PMC4717393.

28. Mangoni A.A., Al Okaily F., Almoallim H. et al. Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: A meta-analysis and review of literature. BMC Rheumatol. 2019; 3: 10. https://doi.org/10.1186/s41927-019-0058-7. PMID: 30886998. PMCID: PMC6408847.